AG-120: Additional Phase I data

Data from 61 evaluable patients with IDH1 mutant-positive hematologic malignancies in an open-label, dose-escalation, U.S. and French Phase I trial showed that total daily doses of 200-1,200 mg oral AG-120 led to an overall response rate (ORR) of 36%, including 11 complete responses, 1 complete response with incomplete platelet recovery (CRp), 6 marrow complete responses (mCR) and 4 partial responses. Median duration of response was 5.6 months. The MTD has not been reached and dose escalation is now closed. AG-120 was well tolerated with diarrhea, fatigue and pyrexia reported as the most common adverse events. Next month, data will be presented at the American Society of Hematology meeting in Orlando. ...